18-FDG PET scan in the staging of recurrent melanoma: Additional value and therapeutic impact

Melanoma Research

Volumn 12, Issue 5, 2002, Pages 479-490

  Stas, M ^a   Stroobants, S ^a   Dupont, P ^a   Gysen, M ^a   Van Hoe, L ^a   Garmyn, M ^a   Mortelmans, L ^a   De Wever, I ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

18 FDG PET scan; Melanoma; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EVALUATION; FEMALE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; RECURRENT DISEASE; SKIN TUMOR; TIME;

ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; RADIOPHARMACEUTICALS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036753487     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200209000-00010     Document Type: Article

References (50)

1. Warburg O. Métabolisme Cellulaire et Métabolisme des Tumeurs. Paris: Librairie Félix Alcan; 1928.
2. Weber G. Enzymology of cancer cells (I). N Engl J Med 1977; 296: 486-492.
3. Weber G. Enzymology of cancer cells (II). N Engl J Med 1977; 10: 10.
4. Coe E. Inhibition of glycolysis in ascites tumor cells preincubated with 2-deoxy-2-fluoro-D-glucose. Biochim Biophys Acta 1972; 264: 319-327.
5. Hoh C, Schiepers C, Seltzer M, Gambhir S, Silverman D, Czernin J, et al. PET in oncology: Will it replace the other modalities? Semin Nucl Med 1997; 27: 94-106.
6. 14C]deoxyglucose uptake and imaging in malignant melanoma. J Surg Res 1991; 50: 643-647.
7. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991; 67: 1544-1549.
8. 18] fluoro-2-deoxy-D-gluxose. J Comput Assist Tomogr 1993; 17: 582-589.
9. Gritters L, Francis I, Zasadny K, Wahl R. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993; 34: 1420-1427.
10. Steinert H, Huch-Böni R, Buck A, Berthold T, Marincek B, Burg G, et al. Malignant melanoma: Staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
11. Strauss L, Tilgen W, Dimitrakopoulou A, Haberkorn U, Knopp M, Helus F, et al. PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior and after therapy. J Nucl Med 1990; 31: 804.
12. Krug B, Dietlein M, Groth W, Stutzer H, Psaras T, Gossmann A, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol 2000; 41: 446-452.
13. Damian D, Fulham M, Thompson E, Thompson J. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-329.
14. Holder W, White RJ, Zuger J, Easton EJ, Greene F. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998; 227: 764-771.
15. Jadvar H, Johnson D, Segall G. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000; 35: 48-51.
16. 18F-fluorodeoxyglucose positron emission tomography. Cancer 1998; 82: 1164-1171.
17. Tyler D, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89: 1019-1025.
18. Valk P, Pounds T, Tesar R, Hopkins D, Haseman M. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23: 737-743.
19. Valk P, Segall G, Johnson D, Pounds T, Tesar R, Jadvar H, et al. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma. J Nucl Med 1997; 38: 90P.
20. Beyer T, Townsend D, Brun T, Kinahan P, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379.
21. Spinks T, Jones T, Gilardi M, Heather J. Physical performance of the latest generation of commercial positron scanner. IEEE Trans Nucl Sci 1988; 35: 721-725.
22. Brix G, Zaers J, Adam L, Bellemann M, Ostertag H, Trojan H, et al. Performance evaluation of a wholebody PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997; 38: 1614-1623.
23. Lange K, Carson R. EM reconstruction algorithms for emission and transmission tomography. J Comput Assist Tomogr 1984; 8: 306-316.
24. Shepp L, Vardi Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans Med Imaging 1982; 1: 113-122.
25. Buzaid A, Sandler A, Mani S, Curtis A, Poo W, Bolognia J, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638-643.
26. 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: A comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 1999; 20: 255-261.
27. Buzaid A, Tinoco L, Ross M, Legha S, Benjamin R. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995; 13: 2104-2108.
28. Ryan L, Kramar A, Borden E. Prognostic factors in metastatic melanoma. Cancer 1993; 71: 2995.
29. Wagner J, Schauwecker D, Hutchins G, Coleman J III. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997; 64: 181-189.
30. Strauss L. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996; 23: 1409-1415.
31. Böni R, Böni R, Steinert H, Burg G, Buck A, Marincek B, et al. Staging of metastatic melanoma by wholebody positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995; 132: 556-562.
32. Bloom A, Adler L, Shuck J. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993; 114: 728-735.
33. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, et al. An evaluation of FDG-PET in the detection and differentiation of thyroid tumours. Nucl Med Commun 1997; 18: 957-963.
34. Patel P, Alibazoglu H, Ali A, Fordham E, LaMonica G. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21: 772-775.
35. Engel H, Steinert H, Buck A, Berthold T, Huch-Böni R, von Schulthess G. Whole-body PET: Physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996; 37: 441-446.
36. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000; 41: 1491-1494.
37. Wagner J, Schauwecker D, Davidson D, Coleman J III, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-1515.
38. Berman C, Reintgen D. Radiologic imaging in malignant melanoma: A review. Semin Surg Oncol 1993; 9: 232-238.
39. Alibazoglu H, Alibazoglu B, Ali A, La Monica G. False-negative FDG PET imaging in a patient with metastatic melanoma and ileal intussusception. Clin Nucl Med 1999; 24: 129.
40. Modorati G, Lucignani G, Landoni C, Freschi M, Trabucchi G, Fazio F, et al. Glucose metabolism and pathological findings in uveal melanoma: Preliminary results. Nucl Med Commun 1996; 17: 1052-1056.
41. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist L, Larsso O, Johansson H, Ringborg U. Central nervous system metastases of cutaneous malignant melanoma - A population-based study. Acta Oncol 1998; 37: 463-470.
42. Khansur T, Sanders J, Das S. Evaluation of staging workup in malignant melanoma. Arch Surg 1989; 124: 847-849.
43. Kroon B, Bergman W, Coebergh J, Ruiter D. Tweede herziene consensus melanoom van de huid. Nederlands Melanoom Werkgroep. [Second revised consensus on skin melanoma. De Nederlandse Melanoom Werkgroep.] Ned Tijdschr Geneeskd 1997; 141: 2015-2019.
44. Reske S, Bares R, Bull U, Guhlmann A, Moser E, Wannenmacher M. klinische wertigheit der positro-nen-emissions-tomographie (PET) bei onkologischen Fragstellungen: Ergebnisse einer interdiziplinären konsensuskonferenz. Nuklearmedizin 1996; 35: 42-52.
45. Bender H, Frohmann J, Grapow M, Hamad K, Schomburg A, Reinhold U, et al. Value of whole-body FDG-PET in the routine staging of malignant melanoma. J Nucl Med 1997; 38: 80-90P.
46. Steinert H, Böni R, Huch-Böni R, Guillong E, Goldsmith R, von Schulthess G. Staging of malignant melanoma with whole-body FDG PET and comparison with conventional tumor screening methods in 119 patients. J Nucl Med 1997; 38: 90P.
47. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995; 131: 1394-1398.
48. Eton O, Legha S, Moon T, Buzaid A, Papadopoulos N, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1988; 16: 1103-1111.
49. Wong J, Skinner K, Kim K, Foshag L, Morton D. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery 1993; 113: 389-394.
50. Dietlein M, Scheidhauer K, Lauterbach K, Schicha H. Qualitätskriterien fur kosten-nutzen-analysen in der onkologischen nuklearmedizin und stand ihrer realisierung. Z Arztl Fortbild Qualitatssich 1999; 93: 49-55.